Navigation Links
Chinese Pharma Market Continues to Grow at a 5-7% Rate in 2009; AMDL Remains on Track to Meet FY09 Financial Targets
Date:4/29/2009

AMDL Inc. Executive Chairman & CEO Douglas MacLellan offers expert insight during exclusive interview with The Wall Street Transcript

TUSTIN, Calif., April 29 /PRNewswire-FirstCall/ -- AMDL Inc. (NYSE Alternext US: ADL), a US-based pharmaceutical company with major operations in China, announced today its Executive Chairman and CEO Mr. Douglas MacLellan has been interviewed and featured in The Wall Street Transcript - a New York weekly investment news publication focused on bringing market news and analysis through exclusive interviews with Wall Street professionals, industry experts and corporate executives.

In an exclusive interview, Mr. MacLellan discusses AMDL's continued focus on becoming a premier pharmaceutical company in the growing $100B China market; the Company's regional expansion and distribution strategy in China; current financing efforts and financial targets for fiscal year 2009; and AMDL's worldwide commercialization strategy for its DR-70 (FDP) cancer test and Human Placenta Extract (HPE) skin care line.

Mr. MacLellan also provided opinion on China pharmaceutical industry saying, "Since the beginning of 2009 the stock market in China has gone up 30%, while the US, European, and other Asian markets have fallen. The Chinese market is going to be the force behind AMDL's sales and marketing for the next few years ... this is good because this market continues to grow and is expected to continue growing between 5-7% from a GDP perspective in 2009."

For the past four consecutive years AMDL has achieved over 100% year-over-year gross revenue growth. Mr. MacLellan provided further insight on AMDL's tremendous growth trajectory saying the Company's FY2009 growth prospects remain strong and executive management is confident AMDL will achieve its FY09 financial guidance of US $62-74 million - which represents another year of 100% growth.

AMDL is featured as the "#1 Small-Cap Stock Pick for 2009" by Flaherty Financial News (www.flahertyfinancialnews.com ), a New York-based investment newsletter, and named one of the Top 5 fastest growing publicly-traded companies in Orange County by international consulting group Deloitte.

The Wall Street Transcript executive interview of Mr. MacLellan has been published and is available on the WST website located at www.twst.com . For additional information on AMDL, its portfolio of international health and beauty products, and 2009 business strategy, visit the Company's website at www.amdl.com or contact AMDL Investor Relations at kszarkowitz@amdl.com .

About AMDL:

Headquartered in Tustin, CA with operations in China, AMDL Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The Company employs over 500 people in the US and China.

Forward Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to AMDL Inc., except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

    AMDL Contact:
    Kristine Szarkowitz
    Director-Investor Relations
    kszarkowitz@amdl.com
    (Tel:) 206.310.5323


'/>"/>
SOURCE AMDL Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Forensic Expert Investigating Chinese Drywall Issue
2. NIAID and Chinese officials sign agreement to foster TB research in Chinas Henan province
3. MIT is pleased to announce that it has received a US$ 200,000 private placement from its future Chinese partners
4. American Heart Association Web Site Now Offers Content Translated Into Traditional Chinese
5. Chinese Colorectal Cancer Drug Market Will More Than Double by 2012
6. Americas Watchdog Calls On President Obama To Get Involved With The Toxic Chinese Drywall Disaster--Now
7. Samplify Expands Global Distribution Channel; Signs Top-Ranked Chinese Distributor, Excelpoint
8. Class Action Filed Against South Florida Developer and Supplier of Defective Chinese Drywall
9. Traditional Chinese Therapy May Help Ease Eczema
10. Defective Chinese Drywall Lawsuit: Florida Homeowners' Associations and Condominium Associations Plagued by Defective Chinese Drywall Urged to Investigate their Rights
11. HUYA Bioscience International Announces Collaboration Agreement With the Beijing Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... , ... The Journal of Pain Research has seen a significant ... data taken from the Scopus database (Elsevier B.V.) and is a measure of a ... journal over a three year period and also the importance of the journals where ...
(Date:2/11/2016)... Petersburg, FL (PRWEB) , ... February 11, 2016 ... ... providers and advocates will discuss how to improve care by making data on ... pediatric heart disease. The Summit on Transparency and Public Reporting of Pediatric and ...
(Date:2/11/2016)... ... February 11, 2016 , ... The Commission for Case Manager ... of Commissioners. Individuals interested in volunteer board service are encouraged to apply. The ... settings and across allied health to contribute to its mission and vision. The ...
(Date:2/11/2016)... ... February 11, 2016 , ... Colorado spine surgeon, Donald Corenman, ... 334 spine surgeons to know in 2016 . The list consists of spine surgeons ... surgery. , Dr. Corenman understands the importance of clinical excellence; he has been ...
(Date:2/11/2016)... DC (PRWEB) , ... February 11, 2016 , ... The ... is based on evaluation of DataPoint’s team dedication and commitment to the ... companies comprising the annual list. The panel’s goal is to recognize and promote technology ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... YORK , Feb. 11, 2016 ... - Companion Diagnostics in Personalized Medicine and Cancer Therapy. ... - High-Growth Diagnostic Testing Markets. - Key ... Testing. - Molecular Diagnostics in Genetic Testing. ... Molecular Diagnostics Markets. - Over-the-Counter Diagnostic Products World ...
(Date:2/11/2016)... 11, 2016 The primary goal of this ... patterns on the usage of liquid biopsy. Key information ... - Timeframe of liquid biopsy adoption amidst future ... Evs—by organization type - Sample inflow to conduct liquid ... stool, serum, and so on. - Correlation analysis of ...
(Date:2/11/2016)... 2016 Stem cells are primitive cells found ... and the capacity to differentiate into mature cell types ... the first mouse embryonic stem cells were derived from ... that the first culturing of embryonic stem cells from ... produced until 2006 As a result of these discoveries, ...
Breaking Medicine Technology: